• Bausch Health published its annual report for fiscal year 2025, citing 11th straight quarter of year-over-year growth.
• Company refinanced USD 9.6 billion of debt to extend maturities and boost financial flexibility.
• DURECT acquisition added late-stage hepatology asset Larsucosterol, which has FDA Breakthrough Therapy designation for alcohol-associated hepatitis.
• China aesthetics move brought Shibo Zhenmei distribution business in-house to expand sales and marketing reach in region.
• Management reiterated plans to separate Bausch + Lomb eye health business, subject to targeted leverage levels and required approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch Health Companies Inc. published the original content used to generate this news brief on April 10, 2026, and is solely responsible for the information contained therein.